• 04/24/2025, Sophia Antipolis, France

    Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements

    Median Technologies releases today its Q1 2025 key financial indicators (unaudited) and provides an update on Q1 operational achievements.
    Read more Download 20250424_PR_Q12025_EN_final.pdf
  • 04/07/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250407_PR_shares_votingrights_March2025.pdf
  • 03/31/2025, Sophia Antipolis, France

    eyonis™ LCS, Median Technologies’ AI-powered Software as a Medical Device for lung cancer screening, confirmed efficacy and safety in RELIVE pivotal study

    Based on a highly enriched cohort, RELIVE study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.
    Read more Download 20250331_PR_RELIVE_finalresults_EN_VF.pdf
  • 03/14/2025, Sophia Antipolis, France

    Median Technologies meets the eligibility conditions for the PEA-PME scheme

    Median Technologies confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria.
    Read more Download 20250314_PR_PEAPMEScheme_EN.pdf
  • 03/07/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250307_PR_shares_votingrights_Feb2025.pdf
  • 03/03/2025, Sophia Antipolis, France

    Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025

    The documents to be communicated within the context of the Shareholders’ General Meeting may be consulted and downloaded on Median Technologies’ website under the “Shareholder Meetings”  section.
    Read more Download 20250303_PR_EGM_March202025_EN-1.pdf
  • 02/26/2025, Sophia Antipolis, France

    Median Technologies to present at TD Cowen’s 45th Annual Health Care Conference

    Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm ET (9:10 pm CET).
    Read more Download 20250226_PR_Cowen2025_EN_final.pdf
  • 02/24/2025, Sophia Antipolis, France

    Median Technologies to showcase its artificial intelligence Software as a Medical Device for lung cancer screening, eyonis™ LCS, at the European Congress of Radiology

    Median Technologies today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2.
    Read more Download 20250224_PR_ECR2025_EN_final.pdf
  • 02/11/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250211_PR_shares_votingrights_jan2025.pdf
  • 02/05/2025, Sophia Antipolis, France

    Median Technologies gives update on drawdowns of the Iris equity line

    Press release – For immediate release – 5:45 pm CET Median Technologies gives update on drawdowns of the Iris equity line Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of […]
    Read more Download 20250205_PR_IRISstatus_EN-1.pdf
    • 1 … 41